HBV

Sepsis Drug Pipeline Research Report 2024: Insights from 30 Companies and 35 Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024
Pharmaceutical, Health, Clinical Trials, Therapy, Acquisition, Blood pressure, HBV, HCV, Hepatitis B virus, Heparin, CRISPR, Infection, Escherichia coli, Melanoma, News, Cancer, Liver cancer, Discovery, Cell, Vaccine, Intensive care medicine, Adrenomedullin, ADM, COVID, Fungal infection, Patient, Protein, Clinical trial, Survival, Endothelium, NDA, Histone, Thymosin

This report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Sepsis pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Sepsis pipeline landscape.
  • A detailed picture of the Sepsis pipeline landscape is provided which includes the disease overview and Sepsis treatment guidelines.
  • This segment of the Sepsis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sepsis drugs.

Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024

Retrieved on: 
Monday, February 26, 2024
Biotechnology, FDA, AIDS, Health, Pharmaceutical, Research, Infectious Diseases, Hospitals, Science, COVID-19, Clinical Trials, Senior, Hepatitis B, CROI, Hook effect, RWE, STR, Viral, Virus, DTG, Mortality, Lenacapavir, Hepatitis, HBV, Vesatolimod, Fungal infection, HIV-1, MDR, PWH, HDV, Boxed warning, European, Islatravir, Tablet, European Commission, Liver disease, Omicron, Conference, Safety, ART, Civil service commission, Abstract, Bictegravir, Natural history, Virology, Emtricitabine, Gilead Sciences, MD, Food, Coinfection, Immunodeficiency, European Economic Area, Risk, Prevalence, Dexamethasone, Patient, Tuberculosis, INSIGHT, HIV, Pharmaceutical industry

Outcomes from pipeline research studies will also provide insights into investigational treatment candidates, including the novel combination regimen of lenacapavir plus bictegravir.

Key Points: 
  • Outcomes from pipeline research studies will also provide insights into investigational treatment candidates, including the novel combination regimen of lenacapavir plus bictegravir.
  • Additionally, a late-breaker oral presentation of Week 24 data from the INSIGHT trial evaluating Biktarvy in people with HIV and tuberculosis will be presented.
  • Gilead will present new data evaluating the safety and efficacy of Hepcludex® (bulevirtide) in people living with the coinfections of HIV, hepatitis B (HBV) and hepatitis delta (HDV).
  • Biktarvy combines the novel, unboosted INSTI bictegravir, with the Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, F/TAF) backbone.

Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness

Retrieved on: 
Wednesday, February 14, 2024
Infectious Diseases, FDA, Genetics, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Oncology, HBV, University College London, FRCS, Toxicology, Precision BioSciences, Gene editing, MD, Food, HBsAg, Precision, Feedback, CccDNA, FCP, Patient, IND, Trial of the century, CTA

Receipt of this regulatory feedback provides alignment and clarity on Precision’s final IND/CTA-enabling preclinical plans and clinical strategy for PBGENE-HBV prior to advancement into Phase 1 clinical studies.

Key Points: 
  • Receipt of this regulatory feedback provides alignment and clarity on Precision’s final IND/CTA-enabling preclinical plans and clinical strategy for PBGENE-HBV prior to advancement into Phase 1 clinical studies.
  • “Based on this feedback, we have initiated the final preclinical studies as well as site selection efforts as we move towards clinical readiness.
  • The pre-IND meeting with FDA provided feedback on overall design for the proposed first-in-human clinical study as well as feedback on the toxicology and specificity assessments.
  • “Given the constructive feedback from the FDA and other regulatory agencies worldwide, I look forward to seeing this novel modality progressing to further assessment in the clinic.”

Fapon at Medlab Middle East 2024: Advancing Local Healthcare through IVD Technologies

Retrieved on: 
Wednesday, February 7, 2024
Partnership, Growth, HCV, Therapy, HIV, Exhibition, HBV, CLIA, IVD, NGS, PCR, Medical device

Dedicated to leveraging its cutting-edge technologies and vast industry experience, Fapon aims to support the growth of the local IVD industry, enhancing local healthcare services while strengthening its global diagnostics ecosystem.

Key Points: 
  • Dedicated to leveraging its cutting-edge technologies and vast industry experience, Fapon aims to support the growth of the local IVD industry, enhancing local healthcare services while strengthening its global diagnostics ecosystem.
  • Committed to empowering local IVD companies and boosting the development of the local healthcare industry in the Middle East, Fapon has established a strategic partnership with the China Innovation Center (C.I.C.)
  • This collaboration aims to introduce Fapon's innovative technologies, products, and services in diagnostics and therapeutics for the medical advancement of the local healthcare industry.
  • Looking ahead, Fapon will remain rooted in the local market in the Middle East, strengthening collaborations with local partners and enhancing healthcare services for the local region.

WestGene Spearheads Oncology Breakthroughs at the 3rd mRNA-Based Therapeutics Summit

Retrieved on: 
Wednesday, January 24, 2024
Speech, Therapy, Research, Nasopharyngeal carcinoma, Summit, IIT, NKT, AI, Government, EMA, BioNTech, CureVac, Cancer, Acquisition, WHO, Drug development, Safety, Intellectual property, Toxicity, Patent, Merck, Messenger, HBV, LNP, Vaccine, Colorectal cancer, CEPI

CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements, Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit in Berlin, Germany.

Key Points: 
  • CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements, Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit in Berlin, Germany.
  • The Summit, held January 23-25, is a key event in the field of mRNA drug development, attracting over 200 specialists from various parts of the world.
  • Founded by two visionary scientists, Dr. Wei Yuquan and Dr. Xiangrong Song, WestGene Biotech is dedicated to pioneering the field of mRNA therapeutics.
  • This project, along with its extensive pipeline, positions WestGene at the forefront of biopharmaceutical innovation and research.

WestGene Spearheads Oncology Breakthroughs at the 3rd mRNA-Based Therapeutics Summit

Retrieved on: 
Wednesday, January 24, 2024
Speech, Therapy, Research, Nasopharyngeal carcinoma, Multimedia, Summit, IIT, NKT, AI, Government, EMA, BioNTech, CureVac, Cancer, Acquisition, WHO, Drug development, Safety, Intellectual property, Toxicity, Patent, Merck, Messenger, HBV, LNP, Vaccine, Colorectal cancer, CEPI

CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements, Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit in Berlin, Germany.

Key Points: 
  • CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements, Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit in Berlin, Germany.
  • Renowned for her pivotal role in mRNA research, Dr. Xiangrong Song, co-founder and CEO of WestGene, presented the latest advances in the company's oncology sector, with a special focus on mRNA-based cancer vaccines.
  • The Summit, held January 23-25, is a key event in the field of mRNA drug development, attracting over 200 specialists from various parts of the world.
  • Founded by two visionary scientists, Dr. Wei Yuquan and Dr. Xiangrong Song, WestGene Biotech is dedicated to pioneering the field of mRNA therapeutics.

Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases

Retrieved on: 
Tuesday, January 9, 2024
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Patient, Therapy, PMM, ATM, Precision, Precision BioSciences, VWAP, Imugene, Cancer, Economics, Optimism, Multiple myeloma, HBV, Immunology, Gene editing, BCMA, Vaccine

“We are excited to extend the utility of our allogeneic CAR T assets into immunology by collaborating with TG Therapeutics as they advance novel treatments for B-cell diseases.

Key Points: 
  • “We are excited to extend the utility of our allogeneic CAR T assets into immunology by collaborating with TG Therapeutics as they advance novel treatments for B-cell diseases.
  • Precision will also receive $2.5 million within 12 months, as an equity investment in Precision’s common stock at 100% premium to the then 30-day VWAP prior to purchase.
  • Upon the achievement of certain near-term clinical milestones, Precision will receive an additional $7.5 million payment in cash and the purchase of Precision common stock by TG Therapeutics at a 100% premium to the then current 30-day VWAP.
  • These transactions are expected to extend our runway and will fund continued development of our wholly owned in vivo gene editing programs.

NIH Deploys Picodya's B-Matrix In Vitro Diagnostics Platform to Detect Global Viral Threats

Retrieved on: 
Monday, January 8, 2024
Partnership, Pandemic, COVID-19, Infection, VRC, NIAID, Fluid mechanics, Research, TEL, HBV, Prostate cancer, MD, National Institutes of Health, Laboratory, Technology policy, EBV, Bangladesh Technical Education Board, IVD, NIH, Global health, Diagnosis, Policy, Vaccine

TEL AVIV, Israel, Jan. 8, 2024 /PRNewswire/ -- Picodya, creator of the first hybrid in vitro diagnostics (IVD) solution for multiplexed point-of-care testing (xPOCT), announced today the deployment of its B-Matrix™ technology in National Institutes of Health (NIH) laboratories. This deployment may enable large-scale global serologic surveillance with real-time monitoring of the immune status of human populations and detection of viral outbreaks, which could further the PREMISE goal of establishing a preemptive repository of candidate immunobiological countermeasures.

Key Points: 
  • Picodya's B-Matrix™ platform is the first xPOCT IVD solution that performs both molecular and immunoassays from many body fluids on a singleplatform.
  • The hybrid and scalable technology aims to deliver lab-comparable test results in a single patient encounter, considerably shortening the diagnostic timeline.
  • "We appreciate the significant benefits the B-Matrix™ platform could bring to the PREMISE program, enabling multiplex testing at scale with high accuracy.
  • The B-Matrix diagnostic system is currently being adopted by global research facilities to help streamline timelines and reduce costs.

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Retrieved on: 
Monday, January 8, 2024
LNP, RNA interference, AASLD, Virology, HBV, Vaccine, Court, Nivolumab, Congress, Clinical trial, Pharmacokinetics, PD, Expert witness, Arbutus, COVID-19, EASL, CFBV, Interim, Investment, Patient, Safety, HBsAg, PD-L1, Pharmaceutical industry

Arbutus plans to announce end-of-treatment data from this trial in the first half of 2024.

Key Points: 
  • Arbutus plans to announce end-of-treatment data from this trial in the first half of 2024.
  • Arbutus plans to announce end-of-treatment data from this portion of the trial in the first half of 2024.
  • Arbutus expects to report preliminary data from the healthy subject portion of this clinical trial, including target engagement and receptor occupancy data, in the first half of 2024.
  • With respect to the Moderna lawsuit, fact discovery is currently on-going with the claim construction hearing scheduled for February 8, 2024.

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

Retrieved on: 
Friday, January 5, 2024
Book, Immune system, IND, PD-1, HBV, HPV, Prostate cancer, Nivolumab, Record, Clinical trial, Cancer, NUC, Bank statement, SNAP, Hepatitis B virus, Human papillomavirus infection, Safety, Autoimmunity, APOLLO, Vaccine

OXFORD, United Kingdom, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today provided a preliminary financial update and announced its 2024 corporate objectives.

Key Points: 
  • OXFORD, United Kingdom, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today provided a preliminary financial update and announced its 2024 corporate objectives.
  • Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
  • “2024 promises to be another exciting year for Barinthus Bio, with multiple data readouts expected across our hepatitis B virus (HBV) infection, human papillomavirus (HPV) infection and prostate cancer programs, as well as the planned initiation of the first in human study of our SNAP platform-based candidate VTP-1000 in Celiac Disease,” said Gemma Brown, Chief Financial Officer of Barinthus Bio.
  • * Barinthus Bio has worldwide rights for all product candidates.